BR112016015078A2 - método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica - Google Patents

método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica

Info

Publication number
BR112016015078A2
BR112016015078A2 BR112016015078A BR112016015078A BR112016015078A2 BR 112016015078 A2 BR112016015078 A2 BR 112016015078A2 BR 112016015078 A BR112016015078 A BR 112016015078A BR 112016015078 A BR112016015078 A BR 112016015078A BR 112016015078 A2 BR112016015078 A2 BR 112016015078A2
Authority
BR
Brazil
Prior art keywords
influenza virus
treating
preventing
pharmaceutical composition
virus infection
Prior art date
Application number
BR112016015078A
Other languages
English (en)
Inventor
Mcbride Jacqueline
Swem Lee
Chai Ning
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112016015078A2 publication Critical patent/BR112016015078A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

a presente invenção fornece anticorpos anti-vírus influenza a efetivos na ligação, neutralização e tratamento do vírus influenza a h7n9, composições que compreendem esses anticorpos e métodos para usar os mesmos.
BR112016015078A 2014-01-27 2015-01-26 método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica BR112016015078A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931949P 2014-01-27 2014-01-27
PCT/US2015/012942 WO2015112994A1 (en) 2014-01-27 2015-01-26 H7n9 influenza a therapies with anti-h7 virus antibodies

Publications (1)

Publication Number Publication Date
BR112016015078A2 true BR112016015078A2 (pt) 2018-01-23

Family

ID=52463191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015078A BR112016015078A2 (pt) 2014-01-27 2015-01-26 método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica

Country Status (10)

Country Link
US (1) US9879066B2 (pt)
EP (1) EP3099710A1 (pt)
JP (1) JP2017508002A (pt)
KR (1) KR20160111948A (pt)
CN (1) CN105934443A (pt)
BR (1) BR112016015078A2 (pt)
CA (1) CA2931012A1 (pt)
MX (1) MX2016009597A (pt)
RU (1) RU2682049C2 (pt)
WO (1) WO2015112994A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
CN109988236B (zh) * 2017-12-30 2022-04-01 中国科学院天津工业生物技术研究所 一种流感病毒抗体的应用
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223285A1 (en) * 2002-03-13 2003-09-29 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
CA2761648C (en) * 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
RU2500426C2 (ru) * 2010-02-27 2013-12-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1, и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1
CN103906763B (zh) * 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和***发育群1和***发育群2的a型流感病毒以及b型流感病毒的人结合分子
US9868952B2 (en) * 2012-07-08 2018-01-16 Sirnaomics, Inc. Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
EA201590731A1 (ru) * 2012-11-13 2015-11-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
CN103450350B (zh) * 2013-07-30 2015-07-01 中国人民解放军军事医学科学院基础医学研究所 人感染h7n9禽流感表位抗原及其在免疫检测试剂中的用途

Also Published As

Publication number Publication date
US9879066B2 (en) 2018-01-30
EP3099710A1 (en) 2016-12-07
RU2016128223A (ru) 2018-03-05
KR20160111948A (ko) 2016-09-27
WO2015112994A1 (en) 2015-07-30
RU2682049C2 (ru) 2019-03-14
CN105934443A (zh) 2016-09-07
JP2017508002A (ja) 2017-03-23
RU2016128223A3 (pt) 2018-08-13
MX2016009597A (es) 2016-10-13
CA2931012A1 (en) 2015-07-30
US20170114121A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
BR112019012342A2 (pt) anticorpos il-11
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
BR112018008103A2 (pt) análogos de celastrol
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
BR112016018082A2 (pt) ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
BR112017005272A2 (pt) uso de cisteamina no tratamento de infecções causadas por leveduras/bolores
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
UY37449A (es) Anticuerpos anti-chikv y usos de éstos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2615 DE 17-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.